Biogen (BIIB) PT Raised to $304 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Biogen (BIIB) PT Raised to $367 at Leerink Partners
August 1, 2016 3:18 PM EDTLeerink Partners analyst Geoffrey Porges raised his price target on Biogen (NASDAQ: BIIB) to $367.00 (from $360.00) but maintained an Market Perform following positive nusinersen data.
Porges commend, "This morning Biogen and Ionis (MP) announced that ENDEAR, a phase 3 study of nusinersen in the treatment of infant-onset (Type I) spinal muscular atrophy (SMA), met its primary pre-specified endpoints following an interim analysis. In a conference call following the... More
Baird Incrementally Positive on Biogen (BIIB) Nusinersen Data; PT to $284
August 1, 2016 3:16 PM EDTBaird analyst Brian Skorney bumped his price target on Biogen (NASDAQ: BIIB) to $284.00 (from $268.00) but lefts his Neutral rating, saying they are incrementally positive on nusinersen interim Phase 3 results.
Skorney commented, "Results are in, earlier than expected, and nusinersen appears to... More
Stifel Affirms Biogen at 'Hold' Following Strong Nusinersen Phase 3 Data
August 1, 2016 3:00 PM EDTStifel affirms Biogen (Nasdaq: BIIB) at Hold after the company and Ionis Pharmaceuticals announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with... More
Biogen (BIIB), Ionis (IONS) Announce Nusinersen Phase 3 Met Primary Endpoint in Infantile-Onset SMA
August 1, 2016 7:34 AM EDTBiogen (Nasdaq: BIIB) and Ionis Pharmaceuticals (Nasdaq: IONS) announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with Type 1) SMA. The analysis found that infants receiving nusinersen experienced a statistically significant improvement in the achievement of motor milestones compared to those who did not receive treatment. Nusinersen demonstrated an acceptable safety profile in the trial. As a result of these findings, Biogen has exercised its option to develop... More
